CARMEN is a national, real-world clinical registry of all adult patients with incident diagnosis of Immune thrombocytopenia (ITP) or Autoimmune Hemolytic anemia (AIHA) patients in France. It is aimed at describing ITP and AIHA clinical features, assessing the real-world risk-benefit ratio of treatments and adherence to guidelines for ITP and AIHA management.
Study Type
OBSERVATIONAL
Enrollment
1,500
Service de Médecine Interne
Toulouse, France
RECRUITINGIncidence of Immune thrombocytopenia (ITP) and AIHA
Number of new cases
Time frame: Baseline
Natural evolution and events
Disease duration. Description of bleeding, infection, thrombosis events
Time frame: Baseline and follow-up
Response
platelet count \>30 G/L and no bleeding
Time frame: 15 years
Complete rate
platelet count \>30 G/L and no bleeding
Time frame: 15 years
Treatment lines
% of patients with each treatment by line of treatments
Time frame: 15 years
Adverse drug reactions
% of patients with adverse drug reaction reported by investigators
Time frame: 15 years
Bleeding
% of patients with bleeding during follow-up
Time frame: 15 years
Rescue treatment
% of patients with any treatment added during the exposure of ongoing treatment
Time frame: 15 years
Adherence to ITP management guidelines.
Percentage of patients who benefitted from the recommended examinations to detect secondary ITP and the percentage of patients who benefitted from the recommended first-line and second line treatments
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 15 years
Events
% of patients with other events of interest like cancer, death, infection, thrombosis
Time frame: 15 years